thrombocytopenia/nutukimas

Nuoroda įrašoma į mainų sritį

Straipsniai Klinikiniai tyrimai Patentai

Pasirinkite rūšiavimo tipą

Puslapis 1 nuo 169 rezultatus

Immune Thrombocytopenia and Obesity: Predictive Relationship.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND Chronic refractory immune thrombocytopenia (ITP) is defined as the failure of any modality to maintain the platelet count above 20 × 103/μL for an appreciable time without unacceptable toxicity. To date, certain predictive factors have been associated with refractory ITP. However, none of

Prolonged anticoagulation after discontinuation of argatroban and warfarin therapy in an obese patient with heparin-induced thrombocytopenia.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

A 32-year-old, morbidly obese African-American woman developed bilateral pulmonary emboli 12 days after undergoing Roux-en-Y gastric bypass surgery. Three days later, after receiving heparin and warfarin, she developed heparin-induced thrombocytopenia type II (HIT-II). An argatroban

Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE To compare dosing strategies using total body weight (actual measured body weight), adjusted body weight, and ideal body weight when starting bivalirudin for the treatment for heparin-induced thrombocytopenia (HIT) in obese patients, and to compare differences in dosing requirements and

Fondaparinux in an obese child with heparin-induced thrombocytopenia and a history of renal failure.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

A 9-year-old obese child with a history of ulcerative colitis was admitted to the intensive care unit for significant blood loss, hemorrhagic shock, and acute renal failure. Following complications from total colectomy secondary to multiple perforations, the patient developed heparin-induced

Danaparoid use for haemodialysis in a morbidly obese patient with heparin-induced thrombocytopenia - Need for a higher than recommended weight-based dosing.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Heparin is widely used to prevent clotting of the extracorporeal circuit during haemodialysis (HD). Heparin-induced thrombocytopenia (HIT) is a potentially devastating immune mediated adverse drug reaction caused by the emergence of antibodies that activate platelets in the presence of

The effect of obesity on the rate of heparin-induced thrombocytopenia.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

: Heparin-induced thrombocytopenia (HIT) occurs in patients receiving heparin-containing products due to the formation of platelet-activating antibodies to heparin and platelet factor 4. Diagnosis includes utilization of a scoring system known as the 4-T score, and HIT laboratory assays. Recently,

Recommendations for the use of the non-obese diabetic/severe combined immunodeficiency mouse model in autoimmune and drug-induced thrombocytopenia: communication from the SSC of the ISTH.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

[The diagnosis of minor hypothyroid states: the HAPO syndrome (hypothyroidism-anemia-thrombopenia-obesity syndrome)].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Impact of obesity on heparin-induced thrombocytopenia in cardiac surgery patients.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Argatroban and renal replacement therapy in a morbidly obese patient with heparin-induced thrombocytopenia: a case report.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Overweight individuals are at increased risk for thrombotic thrombocytopenic purpura.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Our understanding of the pathophysiology of thrombotic thrombocytopenic purpura, TTP, has increased dramatically in the past few years with the identification of the role of ADAMTS13. Nonetheless, risk factors for the development of acute TTP are few. Informally, obesity was felt to be common in

Mefloquine adverse effects with atypical facial lesions in an overweight patient.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND The recommended dosage of mefloquine to treat Plasmodium falciparum infection is 25 mg/kg, with no recommendation for dosage exceeding 1500 mg. We describe an original case of adverse reaction to mefloquine in an overweight patient. METHODS Case report. RESULTS A 32-year-old woman

Prevalence and correlates of thrombosis in adults with immune thrombocytopenia: An NIS study.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND Immune thrombocytopenia (ITP) is increasingly recognized as a thrombophilic disorder. However, no further investigation of risk factors has been conducted to date. This study evaluated classic and disease-specific correlates of thrombosis among ITP patients. We hypothesized the

Vaginosonographically guided paracentesis in a woman with severe thrombocytopenia.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Coagulation disorders and obesity might complicate transabdominal paracentesis. In a woman with severe thrombocytopenia we used the vaginal approach guided by vaginosonography to obtain ascitic fluid for analysis.

Ankstesnis
1
2
3
4
5
6
...
11
12
Kitas

Prisijunkite prie mūsų
„Facebook“ puslapio

Herbal & Natural Medicine

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

Dirba 55 kalbomis
Žolelių gydymas, paremtas mokslu
Vaistažolių atpažinimas pagal vaizdą
Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
Skaitykite mokslines publikacijas, susijusias su jūsų paieška
Ieškokite vaistinių žolelių pagal jų poveikį
Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais